Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study

Journal of Neurology

Volumn 262, Issue 4, 2015, Pages 961-967

  Moccia, Marcello ^a   Lanzillo, Roberta ^a   Costabile, Teresa ^a   Russo, Cinzia ^a   Carotenuto, Antonio ^a   Sasso, Gabriella ^a   Postiglione, Emanuela ^a   De Luca Picione, Carla ^a   Vastola, Michele ^a   Maniscalco, Giorgia Teresa ^a,b   Palladino, Raffaele ^a,c   Brescia Morra, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cognitive; EDSS; Multiple sclerosis; Progression; Relapse; Urate; Uric acid

Indexed keywords

URIC ACID;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COGNITION DISORDERS; COMPLICATION; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COGNITION DISORDERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; URIC ACID; YOUNG ADULT;

EID: 84939964777     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7666-y     Document Type: Article

References (38)

1. Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007) Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56(2):322–330. doi:10.1016/j.brainresrev.2007.07.005
2. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94(6):2528–2533
3. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV (2000) Uric acid A peroxynitrite scavenger inhibits CNS inflammation blood– CNS barrier permeability changes and tissue damage in mouse model of multiple sclerosis. FASEB J 14(5):691–698
4. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA (2000) Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376(6):333–337. doi:10.1006/abbi.2000.1721
5. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308. doi:10.1073/pnas.212645999
6. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680
7. Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9(3):221–226. doi:10.1046/j.1468-1331.2002.00384.x
8. Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40(5):505–508. doi:10.1515/CCLM.2002.088
9. Dujmovic I, Pekmezovic T, Obrenovic R et al (2009) Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. Clin Chem Lab Med 47:848–853. doi:10.1515/CCLM.2009.192
10. Spitsin S, Hooper DC, Mikheeva T, Koprowski H (2001) Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins. Mult Scler 7(3):165–166. doi:10.1177/135245850100700305
11. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, Rosati G (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188. doi:10.1007/s100720200059
12. Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X, Qiu W (2008) Pei Z (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14(2):188–196. doi:10.1177/1352458507082143
13. Ashtari F, Bahar M, Aghaei M, Zahed A (2013) Serum uric acid level in patients with relapsing–remitting multiple sclerosis. J Clin Neurosci 20(5):676–678. doi:10.1016/j.jocn.2012.05.054
14. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelković S, Miljković D, Perić V, Dragutinović G, Marinković J, Lević Z, Mostarica Stojković M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126
15. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, Gottlob I (2004) Serum uric acid levels in optic neuritis. Mult Scler 10(3):278–280
16. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J (2012) Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 34(2):163–171. doi:10.1179/1743132811Y.0000000074
17. Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, Vacca G, Vacchiano V, Nardone A, Triassi M, Morra VB (2014) Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clin Chem Lab Med. doi:10.1515/cclm-2014-0744
18. Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, Laherrán E, Tejero MA (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32(2):347–350. doi:10.1007/s10072-011-0488-5
19. Euser SM, Hofman A, Westendrop RGJ, Breteler MMB (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382. doi:10.1093/brain/awn316
20. Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Spina E, De Rosa A, De Michele G, Santoro L, Barone P, Pellecchia MT (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Disord 20(7):772–775. doi:10.1016/j.parkreldis.2014.03.016
21. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231
22. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286. doi:10.1212/WNL.0000000000000560
23. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366
24. Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 6(6):378–381. doi:10.1177/135245850000600603
25. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33:1444–1452
26. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH (2008) Disability as an outcome in MS clinical trials. Neurology 71(9):624–631. doi:10.1212/01.wnl.0000313034.46883
27. Nocentini U, Giordano A, Di Vincenzo S, Panella M, Pasqualetti P (2006) The Symbol Digit Modalities Test-Oral version: Italian normative data. Funct Neurol 21(2):93–96
28. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, Patti F, Vecchio R, Sorbi S, Trojano M (2006) The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 12(6):787–793. doi:10.1177/1352458506070933
29. Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Luciannatelli E, Paolicelli D, Livrea P, Trojano M (2012) Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One 7(7):e40608. doi:10.1371/journal.pone.0040608
30. Van Schependom J, D’hooghe MB, Cleynhens K, D’hooge M, Haelewyck MC, De Keyser J, Nagels G (2014) The symbol digit modalities test as sentinel test for cognitive impairment in multiple sclerosis. Eur J Neurol 21(9):1219–1225. doi:10.1111/ene.12463 (e71–e72)
31. Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Palladino R, Capo G, Orefice G, Barone P, Pellecchia MT (2015) Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol 22(1):93–98. doi:10.1111/ene.12533
32. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I (2012) Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 45(1–2):26–30. doi:10.1016/j.clinbiochem.2011.09.021
33. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19(4):1331–1336. doi:10.3233/JAD-2010-1330
34. Niklasson F, Hetta J, Degrell I (1988) Hypoxanthine, xanthine, urate and creatinine concentration gradients in cerebrospinal fluid. Ups J Med Sci 93(3):225–232
35. Karg E, Klivényi P, Németh I, Bencsik K, Pintér S, Vécsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246(7):533–539
36. Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D’Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42(10–11):1001–1006. doi:10.1016/j.clinbiochem.2009.03.020
37. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108(6):527–531. doi:10.1016/j.clineuro.2005.08.004
38. Muñoz García D, Midaglia L, Martinez Vilela J, Marín Sánchez M, López González FJ, Arias Gómez M, Dapena Bolaño D, Iglesias Castañón A, Alonso Alonso M, Romero López J (2014) Associated Inosine to interferon: results of a clinical trial in multiple sclerosis. Acta Neurol Scand. doi:10.1111/ane.12333